S-ClassAbout S-Class
A
APREAI Stock Diagnostic Report
Aprea Therapeutics GAAP EPS of -$0.07 beats by $0.16
Aprea Therapeutics reported a GAAP earnings per share (EPS) loss that exceeded expectations.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$0.6600000262260437Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support0.59
Near-Term Resistance0.73
02
FUNDAMENTALS
Financial & Fundamental Analysis
Aprea Therapeutics reported a GAAP EPS of -$0.07, achieving an earnings surprise that exceeded market expectations by $0.16.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current price of $0.66 is positioned between the 20-day support level ($0.59) and resistance level ($0.73), with trading volume at a low 0.43 times, making a split approach near the support level advantageous.
Support0.59
Resistance0.73
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
The earnings announcement significantly exceeded EPS expectations, raising hopes for improved profitability; however, confirmation of the progress of additional clinical pipelines (such as the WEE1 inhibitor) is needed to expand short-term momentum.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-12)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.